Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 12;385(7):664-666.
doi: 10.1056/NEJMc2107799. Epub 2021 Jul 7.

Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants

Venkata-Viswanadh Edara  1 , Benjamin A Pinsky  2 , Mehul S Suthar  3 , Lilin Lai  3 , Meredith E Davis-Gardner  3 , Katharine Floyd  3 , Maria W Flowers  3 , Jens Wrammert  3 , Laila Hussaini  3 , Caroline Rose Ciric  3 , Sarah Bechnak  3 , Kathy Stephens  3 , Barney S Graham  4 , Elham Bayat Mokhtari  4 , Prakriti Mudvari  4 , Eli Boritz  4 , Adrian Creanga  4 , Amarendra Pegu  4 , Alexandrine Derrien-Colemyn  4 , Amy R Henry  4 , Matthew Gagne  4 , Daniel C Douek  4 , Malaya K Sahoo  2 , Mamdouh Sibai  2 , Daniel Solis  2 , Richard J Webby  5 , Trushar Jeevan  5 , Thomas P Fabrizio  5
Affiliations

Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants

Venkata-Viswanadh Edara et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Neutralizing-Antibody Responses against the WA1/2020, B.1.617.1, and B.1.617.2 Variants.
Shown is the neutralizing activity against natural infection with severe acute respiratory syndrome coronavirus 2 among 24 samples from persons who had recovered from coronavirus disease 2019 (obtained 31 to 91 days after symptom onset) (Panel A), 15 samples from persons who had received the mRNA-1273 (Moderna) vaccine (obtained 35 to 51 days after the second dose) (Panel B), and 10 samples from persons who had received the BNT162b2 (Pfizer–BioNTech) vaccine (obtained 7 to 27 days after the second dose) (Panel C). Two independent neutralization assays were performed: activity against B.1.617.1 was compared with that against WA1/2020, and activity against B.1.617.2 was compared with that against WA1/2020. The focus reduction neutralization test (FRNT50 [the reciprocal dilution of serum that neutralizes 50% of the input virus]) geometric mean titers for WA1/2020, B.1.617.1, and B.1.617.2 are shown in each panel. The connecting lines between WA1/2020 and B.1.617.1 or WA1/2020 and B.1.617.2 represent matched serum samples. The horizontal dashed lines along the x axes indicate the limit of detection (FRNT50 geometric mean titer, 20). Normality of the data was determined with the use of the Shapiro–Wilk normality test. Nonparametric pairwise analyses for neutralization titers were performed with the use of the Wilcoxon matched-pairs signed-rank test.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Edara VV, Norwood C, Floyd K, et al. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host Microbe 2021;29(4):516.e3-521.e3. - PMC - PubMed
    1. Liu Z, VanBlargan LA, Bloyet L-M, et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe 2021;29(3):477.e4-488.e4. - PMC - PubMed
    1. Plante JA, Mitchell BM, Plante KS, Debbink K, Weaver SC, Menachery VD. The variant gambit: COVID-19’s next move. Cell Host Microbe 2021;29:508-515. - PMC - PubMed
    1. Cerutti G, Guo Y, Zhou T, et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe 2021;29(5):819.e7-833.e7. - PMC - PubMed
    1. Vanderheiden A, Edara VV, Floyd K, et al. Development of a rapid focus reduction neutralization test assay for measuring SARS-CoV-2 neutralizing antibodies. Curr Protoc Immunol 2020;131(1):e116-e116. - PMC - PubMed

Publication types